Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer
The regorafenib dose‑optimization study (ReDOS) demonstrated that starting at a lower dose of 80 mg daily followed by dose escalation to the standard 160 mg daily improved tolerability and maintained efficacy in patients with metastatic colorectal cancer.
This review provides a clinically relevant appraisal of the regorafenib dose‑optimization study (ReDOS) and the implications for patient management from the perspective of oncologists, advanced practice providers, and pharmacists.
Dose optimisation can reduce toxicity, improve patient adherence, and preserve clinical outcomes, addressing a critical need for safe and effective therapy in metastatic colorectal cancer.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics